Impaired glucose tolerance and indeterminate glycemia in cystic fibrosis

Oral glucose tolerance testing (OGTT) is the primary method to screen for and diagnose cystic fibrosis-related diabetes (CFRD). Diagnostic thresholds as currently defined are based on microvascular complications seen in type 2 diabetes. Abnormal glucose tolerance (AGT) refers to OGTT glucose elevati...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nader Kasim, Swapnil Khare, Zahre Sandouk, Christine Chan
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Oral glucose tolerance testing Impaired glucose tolerance Indeterminate glucose tolerance Indeterminate glycemia Abnormal glucose tolerance Cystic fibrosis Diseases of the endocrine glands. Clinical endocrinology RC648-665
Acceso en línea:	https://doaj.org/article/e1b14997e1744662a0f86b93285e9ee4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e1b14997e1744662a0f86b93285e9ee4
record_format	dspace
spelling	oai:doaj.org-article:e1b14997e1744662a0f86b93285e9ee42021-11-24T04:31:16ZImpaired glucose tolerance and indeterminate glycemia in cystic fibrosis2214-623710.1016/j.jcte.2021.100275https://doaj.org/article/e1b14997e1744662a0f86b93285e9ee42021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2214623721000272https://doaj.org/toc/2214-6237Oral glucose tolerance testing (OGTT) is the primary method to screen for and diagnose cystic fibrosis-related diabetes (CFRD). Diagnostic thresholds as currently defined are based on microvascular complications seen in type 2 diabetes. Abnormal glucose tolerance (AGT) refers to OGTT glucose elevations outside the normal range and encompasses both impaired and indeterminate glucose tolerance. Current guidelines define impaired glucose tolerance (IGT) as a 2-hour glucose of 140–199 mg/dL (7.8–11 mmol/L) and indeterminate glucose tolerance (INDET) as any mid-OGTT glucose ≥ 200 mg/dL (11.1 mmol/L) with a normal fasting and 2 h glucose. There is growing evidence that AGT also has associations with CF-centered outcomes including pulmonary decline, hospitalizations, and weight loss. Here we aim to review the historical emergence of glucose tolerance testing, review relevance to risk stratification for CFRD, discuss alternate cutoffs for identifying AGT earlier, and highlight the need for larger, future studies to inform our understanding of the implications of IGT and INDET on CF health.Nader KasimSwapnil KhareZahre SandoukChristine ChanElsevierarticleOral glucose tolerance testingImpaired glucose toleranceIndeterminate glucose toleranceIndeterminate glycemiaAbnormal glucose toleranceCystic fibrosisDiseases of the endocrine glands. Clinical endocrinologyRC648-665ENJournal of Clinical & Translational Endocrinology, Vol 26, Iss , Pp 100275- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Oral glucose tolerance testing Impaired glucose tolerance Indeterminate glucose tolerance Indeterminate glycemia Abnormal glucose tolerance Cystic fibrosis Diseases of the endocrine glands. Clinical endocrinology RC648-665
spellingShingle	Oral glucose tolerance testing Impaired glucose tolerance Indeterminate glucose tolerance Indeterminate glycemia Abnormal glucose tolerance Cystic fibrosis Diseases of the endocrine glands. Clinical endocrinology RC648-665 Nader Kasim Swapnil Khare Zahre Sandouk Christine Chan Impaired glucose tolerance and indeterminate glycemia in cystic fibrosis
description	Oral glucose tolerance testing (OGTT) is the primary method to screen for and diagnose cystic fibrosis-related diabetes (CFRD). Diagnostic thresholds as currently defined are based on microvascular complications seen in type 2 diabetes. Abnormal glucose tolerance (AGT) refers to OGTT glucose elevations outside the normal range and encompasses both impaired and indeterminate glucose tolerance. Current guidelines define impaired glucose tolerance (IGT) as a 2-hour glucose of 140–199 mg/dL (7.8–11 mmol/L) and indeterminate glucose tolerance (INDET) as any mid-OGTT glucose ≥ 200 mg/dL (11.1 mmol/L) with a normal fasting and 2 h glucose. There is growing evidence that AGT also has associations with CF-centered outcomes including pulmonary decline, hospitalizations, and weight loss. Here we aim to review the historical emergence of glucose tolerance testing, review relevance to risk stratification for CFRD, discuss alternate cutoffs for identifying AGT earlier, and highlight the need for larger, future studies to inform our understanding of the implications of IGT and INDET on CF health.
format	article
author	Nader Kasim Swapnil Khare Zahre Sandouk Christine Chan
author_facet	Nader Kasim Swapnil Khare Zahre Sandouk Christine Chan
author_sort	Nader Kasim
title	Impaired glucose tolerance and indeterminate glycemia in cystic fibrosis
title_short	Impaired glucose tolerance and indeterminate glycemia in cystic fibrosis
title_full	Impaired glucose tolerance and indeterminate glycemia in cystic fibrosis
title_fullStr	Impaired glucose tolerance and indeterminate glycemia in cystic fibrosis
title_full_unstemmed	Impaired glucose tolerance and indeterminate glycemia in cystic fibrosis
title_sort	impaired glucose tolerance and indeterminate glycemia in cystic fibrosis
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/e1b14997e1744662a0f86b93285e9ee4
work_keys_str_mv	AT naderkasim impairedglucosetoleranceandindeterminateglycemiaincysticfibrosis AT swapnilkhare impairedglucosetoleranceandindeterminateglycemiaincysticfibrosis AT zahresandouk impairedglucosetoleranceandindeterminateglycemiaincysticfibrosis AT christinechan impairedglucosetoleranceandindeterminateglycemiaincysticfibrosis
_version_	1718416007515602944

Impaired glucose tolerance and indeterminate glycemia in cystic fibrosis

Ejemplares similares